Last checked at 
(Alliance News) - Angle PLC on Friday said the Laboratory of Translational Oncology, School of Medicine, University of Crete has published peer-reviewed results of new work demonstrating the potential to use Parsortix to assess whether non-small cell lung cancer patients will respond to immunotherapy drugs.
The liquid biopsy company said the study combined, for the first time, an assessment of programmed death-ligand 1 with a second immune checkpoint, indolamine-2,3-dioxygenase, on a patient's circulating tumor cells.
IDO has been shown to promote tumour evasion from the immune surveillance and is also associated with resistance to treatment with anti-PD-1 immune checkpoint inhibitors.
The study demonstrates reduced progression-free survival and overall survival in non-small cell lung cancer patients treated with anti-PD-1 agents.
While a variety of circulating tumor cells systems and approaches were evaluated in matched samples in this study, only circulating tumor cells detection using Angle's Parsortix system was significantly associated with disease progression, the company highlighted.
"In addition to our key focus on securing US Food & Drug Administration clearance for Parsortix, we are progressing the establishment of clinical laboratories so that we can offer laboratory developed tests," said Angle Founder & Chief Executive Andrew Newland.
"The combination of PD-L1 and IDO assessment using Parsortix opens a major market opportunity for ANGLE in the key area of cancer immunotherapy, for a test which we can offer from our clinical laboratories," added Newland.
Angle shares were trading 1.5% higher in London on Friday at 53.18 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
